Literature DB >> 29100010

Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era.

Roger A Barker1, Malin Parmar2, Lorenz Studer3, Jun Takahashi4.   

Abstract

Stem cell-based therapies for Parkinson's disease are moving into a new and exciting era, with several groups pursuing clinical trials with pluripotent stem cell (PSC)-derived dopamine neurons. As many groups have ongoing or completed GMP-level cell manufacturing, we highlight key clinical translation considerations from our recent fourth GForce-PD meeting.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2017        PMID： 29100010     DOI： 10.1016/j.stem.2017.09.014

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  108 in total

Review 1.  Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Authors:  Kai-C Sonntag; Bin Song; Nayeon Lee; Jin Hyuk Jung; Young Cha; Pierre Leblanc; Carolyn Neff; Sek Won Kong; Bob S Carter; Jeffrey Schweitzer; Kwang-Soo Kim
Journal:  Prog Neurobiol       Date:  2018-04-11       Impact factor: 11.685

2.  Advances in stem cell-based regenerative medicine: Despite setbacks and failures, therapies to replace damaged tissue are making their way into the clinic.

Authors:  Philip Hunter
Journal:  EMBO Rep       Date:  2019-04-08       Impact factor: 8.807

Review 3.  Harnessing stem cells and biomaterials to promote neural repair.

Authors:  K F Bruggeman; N Moriarty; E Dowd; D R Nisbet; C L Parish
Journal:  Br J Pharmacol       Date:  2018-12-21       Impact factor: 8.739

Review 4.  Stem cells technology: a powerful tool behind new brain treatments.

Authors:  Lucienne N Duru; Zhenzhen Quan; Talal Jamil Qazi; Hong Qing
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

Review 5.  Integrating CRISPR Engineering and hiPSC-Derived 2D Disease Modeling Systems.

Authors:  Kristina Rehbach; Michael B Fernando; Kristen J Brennand
Journal:  J Neurosci       Date:  2020-02-05       Impact factor: 6.167

6.  Isolation of LMX1a Ventral Midbrain Progenitors Improves the Safety and Predictability of Human Pluripotent Stem Cell-Derived Neural Transplants in Parkinsonian Disease.

Authors:  Isabelle R de Luzy; Jonathan C Niclis; Carlos W Gantner; Jessica A Kauhausen; Cameron P J Hunt; Charlotte Ermine; Colin W Pouton; Lachlan H Thompson; Clare L Parish
Journal:  J Neurosci       Date:  2019-10-22       Impact factor: 6.167

7.  Parkinson's disease grafts benefit from well-timed growth factor.

Authors:  Lorenz Studer; Viviane Tabar
Journal:  Nature       Date:  2020-06       Impact factor: 49.962

Review 8.  Dopamine: Functions, Signaling, and Association with Neurological Diseases.

Authors:  Marianne O Klein; Daniella S Battagello; Ariel R Cardoso; David N Hauser; Jackson C Bittencourt; Ricardo G Correa
Journal:  Cell Mol Neurobiol       Date:  2018-11-16       Impact factor: 5.046

9.  "I Want to Do It, But I Want to Make Sure That I Do It Right." Views of Patients with Parkinson's Disease Regarding Early Stem Cell Clinical Trial Participation.

Authors:  Inmaculada de Melo-Martín; Michael Holtzman; Katrina S Hacker
Journal:  AJOB Empir Bioeth       Date:  2020-06-09

10.  Gene Correction of LGMD2A Patient-Specific iPSCs for the Development of Targeted Autologous Cell Therapy.

Authors:  Sridhar Selvaraj; Neha R Dhoke; James Kiley; Alba Judith Mateos-Aierdi; Sudheer Tungtur; Ricardo Mondragon-Gonzalez; Grace Killeen; Vanessa K P Oliveira; Adolfo López de Munain; Rita C R Perlingeiro
Journal:  Mol Ther       Date:  2019-08-28       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.